Zepbound’s list price ranges from $499 to over $1,000 per month depending on dose, but most people pay significantly less through a combination of manufacturer programs, insurance strategies, and tax-advantaged accounts. The key is knowing which options apply to your situation, because the path to affordable Zepbound looks very different depending on whether you have commercial insurance, Medicare, or no coverage at all.
What Zepbound Actually Costs
Eli Lilly sells Zepbound at a wholesale list price between $499 and $1,086 per fill, but this number is mostly relevant to insurance companies and pharmacies. What you pay depends on your coverage and the format you buy. Zepbound comes in two forms: a single-dose vial and a multi-dose KwikPen. The vials, sold directly to patients through Lilly’s own pharmacy channel called LillyDirect, are priced lower. Through the Zepbound Self-Pay Journey Program, a month of the starting dose (2.5 mg) costs $299, the 5 mg dose runs $399, and all higher doses (7.5 mg through 15 mg) cost $449 per month.
If you refill outside the program’s 45-day window or buy higher doses without it, prices jump considerably. The 12.5 mg and 15 mg vials cost $849 and $1,049 respectively at their regular price. The KwikPen format, available through traditional pharmacies, carries different pricing tiers that generally run higher for most doses.
Lilly’s Self-Pay Program
The most straightforward discount comes directly from Eli Lilly. The Zepbound Self-Pay Journey Program is available to anyone with a valid prescription, regardless of insurance status. You order through LillyDirect, and the medication ships to your door. The monthly costs through this program are:
- 2.5 mg: $299
- 5 mg: $399
- 7.5 mg: $449
- 10 mg: $449
- 12.5 mg: $449
- 15 mg: $449
This program uses single-dose vials rather than the KwikPen. You’ll need to draw the medication with a syringe yourself, which is a trade-off for the lower price. The $449 ceiling on higher doses is significant, since the list price for those same doses can exceed $1,000 through traditional pharmacy channels.
Savings With Commercial Insurance
If you have employer-sponsored or marketplace insurance that doesn’t cover Zepbound, Lilly offers a savings card that brings the cost of the single-dose pen down to $499 per month. For the KwikPen format, the savings card drops prices to $299 for the 2.5 mg dose, $399 for 5 mg, and $449 for doses of 7.5 mg and above. These prices mirror the self-pay program, so the savings card is most useful if you prefer getting your medication through a retail pharmacy rather than ordering vials through LillyDirect.
If your commercial insurance does cover Zepbound, your out-of-pocket cost depends on your plan’s copay or coinsurance structure. Many plans require prior authorization before they’ll pay. The typical criteria insurers look for include a BMI of 30 or higher, and in some cases a qualifying condition like obstructive sleep apnea. Your doctor’s office handles the prior authorization paperwork, but it helps to know what insurers want so you can make sure your medical records support the request.
What to Do After an Insurance Denial
Insurance denials for weight loss medications are common, but they’re not always final. If your plan denies coverage, you have two main options: appeal the decision or pursue an alternative approval pathway. For appeals, your doctor can submit additional clinical documentation showing medical necessity. This might include records of other weight loss interventions you’ve tried, documentation of obesity-related conditions, or sleep study results if you have obstructive sleep apnea.
Some insurers cover Zepbound for specific FDA-approved uses beyond weight loss. These include reducing cardiovascular risk in adults with established heart disease and obesity, treating a liver condition called metabolic dysfunction-associated steatohepatitis (MASH), and treating moderate to severe obstructive sleep apnea in adults with obesity. If you have one of these conditions, your doctor may be able to get approval by framing the prescription around that diagnosis rather than weight loss alone.
Medicare and Medicaid Coverage
Medicare has historically been prohibited from covering weight loss medications. That is changing, but slowly. CMS announced the Medicare GLP-1 Bridge, a short-term demonstration program running from July 1, 2026 through December 31, 2027, that will provide eligible Medicare Part D beneficiaries access to Zepbound when prescribed specifically for weight reduction. This program operates outside the normal Part D benefit, meaning your Part D plan doesn’t need to opt in for you to participate.
There’s an important catch: if your doctor prescribes Zepbound for a use that’s already coverable under standard Part D (like obstructive sleep apnea in adults with obesity), you wouldn’t qualify for the Bridge program. You’d go through your Part D plan’s regular formulary and exception process instead. If you’re on Medicare and can’t wait until mid-2026, the self-pay program at $299 to $449 per month is your most realistic option.
Medicaid coverage varies dramatically by state and is in flux. North Carolina, for example, stopped covering Zepbound solely for obesity treatment as of October 2025, though it still covers the drug for cardiovascular risk reduction, MASH, and obstructive sleep apnea. Other states have their own rules, and these change frequently. Contact your state Medicaid office or check their formulary online for current coverage policies.
Lilly Cares Patient Assistance
If your income falls below certain thresholds, Eli Lilly’s charitable foundation, Lilly Cares, may provide medications at no cost. You must be a permanent U.S. resident (including Puerto Rico and the U.S. Virgin Islands), and your household income before taxes must fall under the program’s limits. These limits are tied to federal poverty guidelines and vary by the medication’s group classification. The income ceilings for a single-person household range from $47,880 to $79,800, and for a four-person household from $99,000 to $165,000, depending on which group Zepbound falls into.
Applying requires your prescribing doctor to submit paperwork on your behalf. The application asks for proof of income and residency. Processing takes time, so this isn’t an overnight solution, but for people who qualify, it can eliminate the cost entirely.
Using HSA and FSA Funds
Prescription weight loss medications like Zepbound are eligible expenses for both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). Because Zepbound requires a prescription to treat a medical condition such as obesity or metabolic syndrome, it qualifies as a recognized medical expense under IRS rules. You can pay for your prescription directly from these accounts or reimburse yourself after paying out of pocket.
The tax advantage is meaningful. HSA contributions are tax-deductible, grow tax-free, and come out tax-free for qualified medical expenses. If you’re in the 22% federal tax bracket and your state taxes income at 5%, paying $449 per month through an HSA effectively saves you around $120 per month compared to paying with after-tax dollars. FSAs work similarly but must be used within the plan year. If you know you’ll be taking Zepbound, increasing your FSA contribution during open enrollment can soften the monthly hit to your budget.
Compounded Tirzepatide Is No Longer Available
During a period when Zepbound was in shortage, some compounding pharmacies legally produced their own versions of tirzepatide at lower prices. That window has closed. The FDA resolved the tirzepatide shortage in December 2024, and as of early 2025, tirzepatide no longer appears on the FDA’s drug shortage list. The period of enforcement discretion that allowed compounding pharmacies to produce tirzepatide has ended for state-licensed pharmacies and expired for outsourcing facilities in March 2025.
Any compounding pharmacy still selling tirzepatide is operating outside FDA guidance. The quality, dosing accuracy, and sterility of these products are not guaranteed the way they are for the brand-name drug. This route carries real risk and is no longer a legitimate cost-saving strategy.
Whether the Cost Is Worth It
In the largest clinical trial of Zepbound for obesity, participants lost an average of 15% of their body weight on the lowest dose (5 mg), 19.5% on the middle dose (10 mg), and 20.9% on the highest dose (15 mg) over 72 weeks. The placebo group lost just 3.1%. For someone weighing 250 pounds, the highest dose translates to roughly 52 pounds lost in a year and a half.
Weight loss of that magnitude typically improves blood pressure, blood sugar, joint pain, sleep apnea severity, and cardiovascular risk markers. Some of those improvements may reduce spending on other medications or medical visits over time. Whether $299 to $449 per month fits your budget depends on your financial situation, but the clinical effect is large enough that many people find the investment changes their health trajectory in ways that smaller, cheaper interventions did not.